MAIA — MAIA Biotechnology, Inc.
—
NYSE ·
Health Care ·
Pharmaceuticals ·
CIK 1878313 ·
Last close
$1.44
Market Cap
$87.55M
52W High
$1.56
52W Low
$1.20
ADV30
901,147
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -6,736,364 | -6,369,652 | 35,322,645 | 34,413,110 | 7,559,877 |
| Dec 2025 | 0 | — | -3,955,922 | -3,628,762 | 9,704,656 | 8,658,031 | 7,328,793 |
| Sep 2025 | 0 | — | -9,360,926 | -8,903,189 | 11,782,021 | 10,891,736 | 11,740,351 |
| Jun 2025 | 0 | — | -5,166,058 | -5,346,963 | 11,045,854 | 10,144,522 | 7,169,170 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-19,953,652
Investing CF
—
Financing CF
$43,497,652
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.75
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-109,631,005
Inventory
—
Receivables
$0
ST Investments
—
EBIT TTM
$-23,123,440
Pretax Income TTM
$-22,396,173
Interest Exp TTM
$57
Analysts
2
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -23,908,336 | -22,396,172 | 9,704,656 | 7,328,793 | — | -18,844,598 |
| Dec 2024 | 0 | -16,877,256 | -23,254,656 | 10,155,279 | 6,520,643 | — | -15,704,461 |
| Dec 2023 | 0 | -20,005,662 | -19,772,905 | 7,566,852 | 7,089,341 | — | -13,071,016 |
| Dec 2022 | 0 | -15,862,576 | -15,769,279 | 12,022,040 | 3,514,247 | — | -12,096,104 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$1.12
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CPIX | CUMBERLAND PHARMACEUTICALS INC | $88.85M | $5.93 | — |
| TELO | Telomir Pharmaceuticals, Inc. | $84.59M | $1.23 | — |
| ZOMDF | Zomedica Corp. | $84.18M | $0.09 | — |
| RLYB | Rallybio Corp | $91.23M | $15.73 | — |
| ACRV | Acrivon Therapeutics, Inc. | $83.89M | $1.96 | — |
News headlines (Yahoo Finance, 1h cache)
MAIA Biotechnology Reports Strong Initial Efficacy Data in Third-Line Non-Small Cell Lung Cancer from Phase 2 THIO-101 Part C Expansion Trial
2026-07-08 13:45 · Yahoo
MAIA Biotechnology Completes International Enrollment in Part C of Phase 2 THIO-101 Expansion Trial in Third-Line Non-Small Cell Lung Cancer
2026-06-25 12:08 · Yahoo
MAIA Biotechnology Opens Enrollment for Phase 2 Expansion Trial of Novel Telomere-Targeting Agent at Winship Cancer Institute of Emory University
2026-06-18 12:30 · Yahoo
MAIA Biotechnology Activates and Opens Enrollment at Second U.S. Clinical Site for International Phase 2 THIO-101 Expansion Trial
2026-06-10 13:15 · Yahoo
MAIA Biotechnology Reports Strong Enrollment and Dosing Momentum in Pivotal Phase 3 Non-Small Cell Lung Cancer Trial
2026-06-04 13:45 · Yahoo
Sector Update: Healthcare Stocks Higher Late Afternoon
2026-06-03 19:43 · Yahoo
MAIA Biotechnology Receives FDA Clearance to Open U.S. Enrollment in Ongoing Phase 2 THIO-101 Trial Expansion
2026-06-03 13:45 · Yahoo
MAIA Biotechnology Announces Open Market Purchases by CEO and Director
2026-06-02 13:45 · Yahoo
MAIA Biotechnology Presents Trial in Progress Poster for Pivotal Phase 3 Clinical Trial of Novel Telomere Targeting Agent at 2026 Annual Meeting of American Society of Clinical Oncology
2026-06-01 12:00 · Yahoo
Diamond Equity Research Releases Update Note on MAIA Biotechnology, Inc. (NYSE: MAIA)
2026-05-18 12:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.